Vitamin D from the diet or synthesized in the skin upon UV-B irradiation is converted in the organism into the active metabolite 1α,25-dihydroxyvitamin D 3 (1, 25(OH) 
Vitamin D regulates gene expression
1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol) is the most active vitamin D metabolite in the organism and a pleiotropic hormone with ample regulatory actions. 1 For decades, lack of adequate vitamin D levels has been linked to impaired intestinal calcium absorption and bone formation (rickets in children, osteomalacia in adults). However, during the past decades, 1,25(OH) 2 D 3 is receiving an increasing interest as epidemiological studies suggest that vitamin D deficiency is associated with a higher risk of developing colon cancer and perhaps other neoplasias, and autoimmune and infectious diseases such as multiple sclerosis and tuberculosis. [2] [3] [4] At the cellular level, 1,25(OH) 2 D 3 modulates proliferation, differentiation, survival, metabolism and physiology, and potentiates the antitumoral activity of certain chemotherapeutic agents, in a cell-type-and -context-dependent manner. [5] [6] [7] [8] [9] [10] According to the classical model of action, 1,25(OH) 2 D 3 binds to and activates a transcription factor of the nuclear receptor superfamily, the vitamin D receptor (VDR), and modulates the transcription rate of its target genes. 11 1,25(OH) 2 D 3 is a major regulator of gene expression in higher organisms as VDR is expressed in at least 38 human cell types. 12 In line with this, genome-wide studies using chromatin immunoprecipitation coupled with ultra highthroughput sequencing (ChIP-Seq) have revealed a high number and variety of VDR binding sites in genes associated to many different cell functions and physiological and pathological conditions. [13] [14] [15] [16] This mechanism of action has progressively become more comprehensive and complex with the finding that VDR is partially located outside the cell nucleus where it mediates the effects of 1,25(OH) 2 D 3 in the opening of ion channels and in the activity of enzymes such as kinases, phosphatases, and phospholipases. 17 Remarkably, at least part of these extranuclear signaling pathways converges and contributes to the control of gene transcription by VDR. 18, 19 Moreover, 1,25(OH) 2 D 3 regulates genes that seem to lack VDR binding sites, 15 and exerts post-translational gene regulatory effects by controlling the expression of multiple proteases and protease inhibitors. 20 In addition, in certain systems VDR has been found to interact with other transcription regulators such as β-catenin and FoxO factors having ligand-dependent or -independent effects.
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Histone demethylation
The key role of epigenetic regulation, defined as chromatin changes affecting nucleosomal histones or DNA methylation, on transcription activation and repression is well recognized.
The tails of the four core histones exposed on the nucleosome surface are subjected to a variety of enzyme-catalyzed post-translational modifications including acetylation, methylation, ubiquitylation, ADP-ribosylation, phosphorylation and sumoylation, which may occur singly or in combination. 23, 24 Histone methylation is more complex than any other posttranslational histone modification. It can occur on either lysines or arginines residues, and the consequence of its methylation can be either positive or negative towards transcriptional expression depending on the type of residue and on its position within the histone. Further complexity results from the fact that there can be multiple methylated states on each residue, as lysines can be mono-(me1), di-(me2) or tri-(me3) methylated, and arginines can be mono-or dimethylated. 25, 26 The methylation state can lead to different functional consequences, as effector proteins might recognize one modification and have little affinity for other on the same residue. 27 Histone methylation is a reversible process mediated by two antagonizing groups of enzymes: histone methytransferases (HMT) and histone demethylases (HDM). [27] [28] [29] Misregulation of histone modifications may lead to deregulation of gene expression and perturbation of cellular identity, which may contribute to cancer initiation, progression and/or metastasis. 30, 31 5
There are three distinct classes of enzymes capable of removing methylation marks.
The first class includes peptidylarginine deiminase (PADI) enzymes that convert methylated residues of arginine to citrulline through a demethylimination reaction. Besides their clear role antagonizing methylarginine modifications, PADI enzymatic activity does not result in the production of an unmodified arginine, and for that fail to meet the requirements of a true HDM. 27, 32 Lysine specific demethylase (LSD)-1 was the founding member of the second class of enzymes and the first true demethylase to be described. 33 The demethylation reaction catalyzed by LSDs limits these enzymes to use only mono-and dimethylated lysine residues as substrates. 27, 34 The third and largest group of HDM enzymes contains a Jumonji C (JmjC) domain and catalyzes site-specific demethylation of mono-, di-and trimethylated lysines and, in the case of one particular member (JMJD6), also the site-specific demethylation of monoand dimethylated arginines. 28, 35, 36 37 As there was no literature for JMJD4, we focused our studies on JMJD3. This enzyme, also known as KDM6B, was the first specific demethylase of the trimethylated lysine 27 of histone H3 (H3K27me3) described. [38] [39] [40] [41] Supporting the second mechanism, a ChIP-Seq study conducted by Dr. Natoli's group suggested that the involvement of Jmjd3 in tuning transcriptional regulation by LPS in mouse macrophages is largely independent of its H3K27 demethylase activity. 69 Unexpectedly, Jmjd3 was found to be located preferentially at gene transcription start sites with upregulated H3K4me3, a histone mark associated with active genes or poised for activation. Importantly, only a minority of Jmjd3 peaks were associated with neighbouring H3K27me3 peaks, while
Jmjd3 deletion resulted in defective recruitment of RNA polymerase II but not in altered H3K27me3 signals. 69 Moreover, the assumption that histones are the only substrate for HDMs may be incorrect, as it has been demonstrated that in human cancer cell lines LSD1 interacts with and dynamically regulates lysine methylation of the p53 protein, thus repressing p53-mediated transcriptional activation. 70 Therefore, the possibility that non-histone substrates and/or non-enzymatic activities of HDMs may mediate the biological actions of these enzymes should be considered. 71 It is possible that JMJD3, as well as other JmjC domaincontaining enzymes, may engender demethylation of non-histone substrates and/or other actions than protein demethylation, and that these unknown functions could account for the observed effects in our studies.
Interestingly, we found that the overexpression of an inactive JMJD3 C-terminal region harbouring a point mutation in the iron-binding centre (MUT 1141-1641) in SW480-ADH cells has an inhibitory effect on the regulation of 1,25(OH) 2 D 3 target genes similar to that observed in shJMJD3 cells. 37 Although these results would favor a demethylasedependent mechanism, it is unknown whether the mutation generates allosteric changes in the JMJD3 protein that would circumvent and/or affect other putative unknown functions. In an attempt to clarify this point and taking advantage of the available Jmjd3 ChIP-Seq data in mouse macrophages, 69 we analyzed in that system if Jmjd3 (upon induction by LPS) is recruited to Cyp24a1 and Cdh1 gene loci. These two genes are 1,25(OH) 2 D 3 targets whose induction is reduced by JMJD3 knockdown or by the expression of JMJD3 MUT 1141-1641 in SW480-ADH cells. 37 We found that Jmjd3 binds to a region upstream (40, 861) converted to bedGraph format and overlaid on mouse genome assembly (mm8) as a custom track using the UCSC genome browser. Peak height represents the number of overlapping tags observed in that region and width of peak suggests the area covered by the tags.
